Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pre-Treatment HIV Drug Resistance and Genetic Diversity in Cameroon: Implications for First-Line Regimens.
Fokam J, Chenwi CA, Tala V, Takou D, Santoro MM, Teto G, Dambaya B, Anubodem F, Semengue ENJ, Beloumou G, Djupsa S, Assomo E, Fokunang C, Alteri C, Billong S, Bouba NP, Ajeh R, Colizzi V, Mbanya D, Ceccherini-Silberstein F, Perno CF, Ndjolo A. Fokam J, et al. Among authors: colizzi v. Viruses. 2023 Jun 28;15(7):1458. doi: 10.3390/v15071458. Viruses. 2023. PMID: 37515146 Free PMC article.
High genotypic diversity of human papillomavirus among women in Cameroon: implications for vaccine effectiveness.
Tchouaket MCT, Fokam J, Sosso SM, Semengue ENJ, Yagai B, Simo RK, Sando Z, Nka AD, Tchinda GP, Takou D, Fainguem N, Chenwi C, Ka'e AC, Abba A, Zam MKN, Perno CF, Colizzi V, Ndjolo A. Tchouaket MCT, et al. Among authors: colizzi v. IJID Reg. 2022 Oct 6;5:130-136. doi: 10.1016/j.ijregi.2022.09.014. eCollection 2022 Dec. IJID Reg. 2022. PMID: 36313603 Free PMC article.
Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.
Nka AD, Bouba Y, Teto G, Semengue ENJ, Takou DK, Ngueko AMK, Fabeni L, Carioti L, Armenia D, Pabo W, Dambaya B, Sosso SM, Colizzi V, Perno CF, Ceccherini-Silberstein F, Santoro MM, Fokam J, Ndjolo A. Nka AD, et al. Among authors: colizzi v. J Antimicrob Chemother. 2022 Dec 23;78(1):272-275. doi: 10.1093/jac/dkac388. J Antimicrob Chemother. 2022. PMID: 36411257
Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model.
Semengue ENJ, Fokam J, Etame NK, Molimbou E, Chenwi CA, Takou D, Mossiang L, Meledie AP, Yagai B, Nka AD, Dambaya B, Teto G, Ka'e AC, Beloumou GA, Djupsa Ndjeyep SC, Abba A, Kengni AMN, Tommo Tchouaket MC, Bouba NP, Billong SC, Sosso SM, Colizzi V, Perno CF, Kouanfack C, Zoung-Kanyi Bissek AC, Eben-Moussi E, Santoro MM, Ceccherini-Silberstein F, Ndjolo A. Semengue ENJ, et al. Among authors: colizzi v. Viruses. 2022 Dec 21;15(1):18. doi: 10.3390/v15010018. Viruses. 2022. PMID: 36680058 Free PMC article.
Evaluation of archived drug resistance mutations in HIV-1 DNA among vertically infected adolescents under antiretroviral treatment in Cameroon: Findings during the COVID-19 pandemic.
Ka'e AC, Fokam J, Togna Pabo WLR, Nanfack A, Ngoufack Jagni Semengue E, Bouba Y, Nka AD, Tetang S, Beloumou G, Takou D, Chenwi C, Tommo Tchouaket MC, Abba A, Djupsa S, Sosso SM, Pamen NB, Otshudiema JO, Boum Y 3rd, Colizzi V, Ndjolo A, Perno CF, Ceccherini-Silberstein F, Santoro MM. Ka'e AC, et al. Among authors: colizzi v. HIV Med. 2023 Jun;24(6):691-702. doi: 10.1111/hiv.13459. Epub 2023 Jan 30. HIV Med. 2023. PMID: 36717222
HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis.
Ngoufack Jagni Semengue E, Santoro MM, Ndze VN, Ka'e AC, Yagai B, Nka AD, Dambaya B, Takou D, Teto G, Fabeni L, Colizzi V, Perno CF, Ceccherini-Silberstein F, Fokam J. Ngoufack Jagni Semengue E, et al. Among authors: colizzi v. PLOS Glob Public Health. 2022 Oct 11;2(10):e0000826. doi: 10.1371/journal.pgph.0000826. eCollection 2022. PLOS Glob Public Health. 2022. PMID: 36962573 Free PMC article.
Pre-existing immunity to SARS-CoV-2 before the COVID-19 pandemic era in Cameroon: A comparative analysis according to HIV-status.
Aissatou A, Fokam J, Semengue ENJ, Takou D, Ka'e AC, Ambe CC, Nka AD, Djupsa SC, Beloumou G, Ciaffi L, Tchouaket MCT, Nayang ARM, Pabo WLT, Essomba RG, Halle EGE, Okomo MC, Bissek AZ, Leke R, Boum Y 2nd, Mballa GAE, Montesano C, Perno CF, Colizzi V, Ndjolo A. Aissatou A, et al. Among authors: colizzi v. Front Immunol. 2023 Mar 8;14:1155855. doi: 10.3389/fimmu.2023.1155855. eCollection 2023. Front Immunol. 2023. PMID: 37090738 Free PMC article.
Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics.
Fokam J, Nka AD, Mamgue Dzukam FY, Efakika Gabisa J, Bouba Y, Tommo Tchouaket MC, Ka'e AC, Ngoufack Jagni Semengue E, Takou D, Moudourou S, Fainguem N, Pabo W, Nayang Mundo RA, Kengni Ngueko AM, Ambe Chenwi C, Flore Yimga J, Nnomo Zam MK, Simo Kamgaing R, Tangimpundu C, Kamgaing N, Njom-Nlend AE, Ndombo Koki P, Kesseng D, Ndiang Tetang S, Kembou E, Ebiama Lifanda L, Pamen B, Ketchaji A, Saounde Temgoua E, Billong SC, Zoung-Kanyi Bissek AC, Hadja H, Halle EG, Colizzi V, Perno CF, Sosso SM, Ndjolo A. Fokam J, et al. Among authors: colizzi v. Medicine (Baltimore). 2023 May 19;102(20):e33737. doi: 10.1097/MD.0000000000033737. Medicine (Baltimore). 2023. PMID: 37335723 Free PMC article.
Laboratory Based Surveillance of HIV-1 Acquired Drug Resistance in Cameroon: Implications for Use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line Regimens.
Fokam J, Chenwi CA, Takou D, Santoro MM, Tala V, Teto G, Beloumou G, Semengue ENJ, Dambaya B, Djupsa S, Kembou E, Bouba NP, Ajeh R, Cappelli G, Mbanya D, Colizzi V, Ceccherini-Silberstein F, Perno CF, Ndjolo A. Fokam J, et al. Among authors: colizzi v. Viruses. 2023 Aug 2;15(8):1683. doi: 10.3390/v15081683. Viruses. 2023. PMID: 37632026 Free PMC article.
351 results